Literature DB >> 19909083

Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses.

Yi Liu1, John McNevin, Morgane Rolland, Hong Zhao, Wenjie Deng, Janine Maenza, Claire E Stevens, Ann C Collier, M Juliana McElrath, James I Mullins.   

Abstract

BACKGROUND: The epitope specificities and antiviral activities of class I HLA-restricted CD8(+) T cells, especially those induced during human immunodeficiency virus type 1 (HIV-1) primary infection, are important considerations in designing HIV-1 vaccines. Conserved epitopes may be more commonly and persistently recognized than variable epitopes, as they may be more likely to be present in infecting viruses. However, some studies have shown preferential or similar targeting of variable versus conserved epitopes during primary infection.
METHODS: We analyzed cytotoxic T-lymphocyte (CTL) responses toward predefined conserved and variable epitopes in 45 subjects during primary (n = 34) and/or chronic infection (n = 16).
RESULTS: Conserved and variable CTL epitopes were recognized with similar probabilities, whereas conserved epitopes generally elicited subdominant responses during both primary and chronic infection. During primary infection, CTL responses against Gag versus responses against Env and variable epitopes tended to be associated with lower and higher viral loads, respectively. During chronic infection, Env-specific responses tended to be associated with lower CD4(+) cell counts.
CONCLUSIONS: Subdominant CTL recognition of conserved HIV-1 epitopes commonly occurs from the primary through chronic stages of HIV-1 infection. These findings underscore the challenge in designing T cell-based vaccines that can induce immunodominant CTL responses to conserved HIV-1 regions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19909083      PMCID: PMC2783836          DOI: 10.1086/648401

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  43 in total

1.  HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity.

Authors:  Mathias Lichterfeld; Xu G Yu; Daniel Cohen; Marylyn M Addo; Jessica Malenfant; Beth Perkins; Eunice Pae; Mary N Johnston; Daryld Strick; Todd M Allen; Eric S Rosenberg; Bette Korber; Bruce D Walker; Marcus Altfeld
Journal:  AIDS       Date:  2004-07-02       Impact factor: 4.177

2.  Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.

Authors:  L Musey; J Hughes; T Schacker; T Shea; L Corey; M J McElrath
Journal:  N Engl J Med       Date:  1997-10-30       Impact factor: 91.245

3.  Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses.

Authors:  Florian Bihl; Nicole Frahm; Loriana Di Giammarino; John Sidney; Mina John; Karina Yusim; Tonia Woodberry; Kaori Sango; Hannah S Hewitt; Leah Henry; Caitlyn H Linde; John V Chisholm; Tauheed M Zaman; Eunice Pae; Simon Mallal; Bruce D Walker; Alessandro Sette; Bette T Korber; David Heckerman; Christian Brander
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

4.  Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP).

Authors:  M Bunce; G C Fanning; K I Welsh
Journal:  Tissue Antigens       Date:  1995-02

Review 5.  The packaging and maturation of the HIV-1 Pol proteins.

Authors:  Melissa Hill; Gilda Tachedjian; Johnson Mak
Journal:  Curr HIV Res       Date:  2005-01       Impact factor: 1.581

6.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

7.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection.

Authors:  Jianhong Cao; John McNevin; Sarah Holte; Lisa Fink; Lawrence Corey; M Juliana McElrath
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities.

Authors:  Nicole Frahm; B T Korber; C M Adams; J J Szinger; R Draenert; M M Addo; M E Feeney; K Yusim; K Sango; N V Brown; D SenGupta; A Piechocka-Trocha; T Simonis; F M Marincola; A G Wurcel; D R Stone; C J Russell; P Adolf; D Cohen; T Roach; A StJohn; A Khatri; K Davis; J Mullins; P J R Goulder; B D Walker; C Brander
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1.

Authors:  Marcus Altfeld; Elizabeth T Kalife; Ying Qi; Hendrik Streeck; Mathias Lichterfeld; Mary N Johnston; Nicole Burgett; Martha E Swartz; Amy Yang; Galit Alter; Xu G Yu; Angela Meier; Juergen K Rockstroh; Todd M Allen; Heiko Jessen; Eric S Rosenberg; Mary Carrington; Bruce D Walker
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

View more
  18 in total

1.  Acute-Phase CD4+ T Cell Responses Targeting Invariant Viral Regions Are Associated with Control of Live Attenuated Simian Immunodeficiency Virus.

Authors:  Matthew S Sutton; Amy Ellis-Connell; Ryan V Moriarty; Alexis J Balgeman; Dane Gellerup; Gabrielle Barry; Andrea M Weiler; Thomas C Friedrich; Shelby L O'Connor
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

2.  Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine.

Authors:  Lauren Levitz; Ousmane A Koita; Kotou Sangare; Matthew T Ardito; Christine M Boyle; John Rozehnal; Karamoko Tounkara; Sounkalo M Dao; Youssouf Koné; Zoumana Koty; Soren Buus; Leonard Moise; William D Martin; Anne S De Groot
Journal:  Vaccine       Date:  2012-10-24       Impact factor: 3.641

3.  Early HLA-B*57-restricted CD8+ T lymphocyte responses predict HIV-1 disease progression.

Authors:  Catherine A Brennan; F Javier Ibarrondo; Catherine A Sugar; Mary Ann Hausner; Roger Shih; Hwee L Ng; Roger Detels; Joseph B Margolick; Charles R Rinaldo; John Phair; Lisa P Jacobson; Otto O Yang; Beth D Jamieson
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

4.  Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells.

Authors:  Zaza M Ndhlovu; Alicja Piechocka-Trocha; Seanna Vine; Ashley McMullen; Kegakilwe C Koofhethile; Phillip J R Goulder; Thumbi Ndung'u; Dan H Barouch; Bruce D Walker
Journal:  J Immunol       Date:  2011-05-16       Impact factor: 5.422

5.  Fluidity of HIV-1-specific T-cell responses during acute and early subtype C HIV-1 infection and associations with early disease progression.

Authors:  Mandla Mlotshwa; Catherine Riou; Denis Chopera; Debra de Assis Rosa; Roman Ntale; Florette Treunicht; Zenda Woodman; Lise Werner; Francois van Loggerenberg; Koleka Mlisana; Salim Abdool Karim; Carolyn Williamson; Clive M Gray
Journal:  J Virol       Date:  2010-09-08       Impact factor: 5.103

6.  Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes.

Authors:  Liguo Niu; James M Termini; Saravana K Kanagavelu; Sachin Gupta; Morgane M Rolland; Viraj Kulkarni; George N Pavlakis; Barbara K Felber; James I Mullins; Margaret A Fischl; Geoffrey W Stone
Journal:  Vaccine       Date:  2011-01-15       Impact factor: 3.641

7.  Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design.

Authors:  Pratima Kunwar; Natalie Hawkins; Warren L Dinges; Yi Liu; Erin E Gabriel; David A Swan; Claire E Stevens; Janine Maenza; Ann C Collier; James I Mullins; Tomer Hertz; Xuesong Yu; Helen Horton
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

8.  Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges.

Authors:  Eung-Jun Im; Jessie P Hong; Yaowaluck Roshorm; Anne Bridgeman; Sven Létourneau; Peter Liljeström; Mary Jane Potash; David J Volsky; Andrew J McMichael; Tomáš Hanke
Journal:  PLoS Pathog       Date:  2011-05-19       Impact factor: 6.823

9.  Dynamics of viral evolution and CTL responses in HIV-1 infection.

Authors:  Yi Liu; John P McNevin; Sarah Holte; M Juliana McElrath; James I Mullins
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

10.  CD8(+) T-cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen Types.

Authors:  Stephen A Migueles; Daniel Mendoza; Matthew G Zimmerman; Kelly M Martins; Sushila A Toulmin; Elizabeth P Kelly; Bennett A Peterson; Sarah A Johnson; Eric Galson; Kate O Poropatich; Andy Patamawenu; Hiromi Imamichi; Alexander Ober; Catherine A Rehm; Sara Jones; Claire W Hallahan; Dean A Follmann; Mark Connors
Journal:  EBioMedicine       Date:  2014-12-22       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.